Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women

Nature Clinical Practice Endocrinology and Metabolism

Volumn 2, Issue 4, 2006, Pages 200-210

  Colao, Annamaria ^a   Di Sarno, Antonella ^b   Guerra, Ermelinda ^a   De Leo, Monica ^a   Mentone, Alberto ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

Author keywords

Bromocriptine; Cabergoline; Dopamine; Prolactin; Prolactinomas

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DISEASE COURSE; DIZZINESS; DOWN SYNDROME; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; ECTOPIC PREGNANCY; FEMALE; FETUS MALFORMATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONE RELEASE; HOT FLUSH; HUMAN; HYDATIDIFORM MOLE; HYDROCEPHALUS; HYPERPROLACTINEMIA; HYPOPHYSIS FUNCTION; HYPOPHYSIS TUMOR; HYPOTENSION; LEG CRAMP; LUNG FIBROSIS; LUNG INFILTRATE; MALE; MANIA; MEGAURETER; MICROADENOMA; NAUSEA; NEUROLOGIC DISEASE; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PLEURA EFFUSION; PLEURA THICKENING; PREGNANCY TERMINATION; PRIORITY JOURNAL; PROLACTINOMA; PSYCHOSIS; RAYNAUD PHENOMENON; RECURRENCE RISK; REFLUX ESOPHAGITIS; RETROPERITONEAL FIBROSIS; REVIEW; SIDE EFFECT; SPONTANEOUS ABORTION; SYNCOPE; TREATMENT OUTCOME; VASOSPASM; VERTIGO; VISUAL FIELD DEFECT; VOMITING; XEROSTOMIA;

ADENOMA; ANTINEOPLASTIC AGENTS; BROMOCRIPTINE; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; PROLACTIN; PROLACTINOMA; SEX CHARACTERISTICS;

EID: 33646594121     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0160     Document Type: Review

References (78)

1. Mindermann T and Wilson CH (1994) Age-related and gender-related occurrence of pituitary tumors. Clin Endocrinol 41: 359-364
2. Partington MD et al. (1994) Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. J Neurosurg 80: 209-216
3. Colao A (2003) Pituitary tumors in childhood. In Pediatric Endocrinology, chapter 3 (Ed. New MI) Endotext.com [http://www.endotext.org/pediatrics/ pediatrics3/pediatricsframe3.htm] (accessed 20 January 2006)
4. Colao A and Lombardi G (1998) Growth-hormone and prolactin excess. Lancet 352: 1455-1461
5. Beckers A et al. Approaching the true prevalence of pituitary tumors. ENEA (The European Neuroendocrine Association) Meeting (NA): 2004 24-27 April; Sorrento, Italy, 23, [Abstract #1.1]
6. Colao A et al. (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148: 325-331
7. Ambrosi B et al. (1980) Prolactin and sexual function. JAMA 244: 2608
8. Carter JN et al. (1978) Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med 299: 847-852
9. Koppelman MC et al. (1984) Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases. Ann Intern Med 100: 115-121
10. March CM et al. (1981) Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 139: 835-844
11. Schlechte J et al. (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68: 412-418
12. Sisam DA et al. (1987) The natural history of untreated microprolactinomas. Fertil Steril 48: 67-71
13. Von Werder K et al. (1982) Development of hyperprolactinemia in patients with adenomas with and without prior operative treatment. Excerpta Med Int Congr Ser 584: 175-188
14. Weiss MH et al. (1983) Natural history of microprolactinomas: six-year follow-up. Neurosurgery 12: 180-183
15. Molitch ME et al. (1997) Management of prolactinomas. J Clin Endocrinol Metab 82: 996-1000
16. Vance ML et al. (1984) Bromocriptine. Ann Intern Med 100: 78-91
17. Molitch ME et al. (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60: 698-705
18. Bevan JS et al. (1992) Dopamine agonists and pituitary tumour shrinkage. Endocr Rev 13: 220-240
19. Webster J et al. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. N Engl J Med 331: 904-909
20. Ferrari CI et al. (1997) Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol 46: 409-413
21. Verhelst J et al. (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84: 2518-2522
22. Colao A et al. (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pre-treated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85: 2247-2252
23. Di Sarno A et al. (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition and therapeutic strategy. J Clin Endocrinol Metab 86: 5256-5261
24. Liuzzi A et al. (1985) Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313: 656-659
25. Eguchi K et al. (1995) In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors. Endocr J 42: 153-161
26. Eguchi K et al. (1995) Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies. Endocr J 42: 413-420
27. Pontiroli AE et al. (1987) Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3′-dimethylaminopropyl)-3-(6′ allylergoline-8′-β-carbonyl)urea-diphosphate (fce 21336). Br J Clin Pharmacol 23: 433-438
28. Andreotti AC et al. (1995) Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers. J Clin Endocrinol Metab 80: 841-845
29. Melis GB et al. (1987) Dose related prolactin-inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal and hyperprolactinemic women. J Clin Endocrinol Metab 65: 541-545
30. Johnston DG et al. (1983) Hyperprolactinemia. Long-term effects of bromocriptine. Am J Med. 75: 868-874
31. Johnston DG et al. (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerized tomography. Lancet 2: 187-192
32. Bergh T et al. (1982) Menstrual function and prolactin levels after long-term bromocriptine treatment of prolactinaemic amenorrhea. Clin Endocrinol 16: 587-593
33. Maxson WS et al. (1984) Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertil Steril 41: 218-223
34. Zarate A et al. (1983) Follow-up of patients with prolactinoma after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol 104: 139-142
35. Moriondo P et al. (1985) Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60: 764-772
36. Winkelmann W et al. (1985) Persisting normoprolactinemia after withdrawal of bromocriptine long-term therapy in patients with prolactinomas. In Prolactin. Basic and Clinical Correlates, 817-822 (Eds MacLeod RM et al.) Padova, Italy: Liviana Press
37. Wang C et al. (1987) Long-term treatment of hyperprolactinemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol 27: 363-371
38. Passos VQ et al. (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87: 3578-3582
39. Biswas M et al. (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol 63: 26-31
40. van't Verlaat JW and Croughs RJ (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumour size. Clin Endocrinol 34: 175-178
41. Thorner MO et al. (1981) Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 53: 480-483
42. Vance ML et al. (1984) Drugs five years later. Bromocriptine. Ann Intern Med 100: 78-91
43. Orrego JJ et al. (2000) Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. Pituitary 3: 189-192
44. Landolt AM and Osterwalder V (1984) Perivascular fibrosis in prolactinomas: is it increased by bromocriptine? J Clin Endocrinol Metab 58: 1179-1183
45. Krupp P and Monka C (1987) Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 65: 823-827
46. Turkalj I et al. (1982) Surveillance of bromocriptine in pregnancy. JAMA 247: 1589-1591
47. Klibanski A and Greenspan SL (1986) Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 315: 542-546
48. Webster J et al. (1993) The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinemic disorders: an open, uncontrolled, multicentre study. Clin Endocrinol 39: 323-329
49. Biller BMK et al. (1996) Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81: 2338-2343
50. Colao A et al. (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82: 3574-3579
51. Cannavo S et al. (1999) Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest 22: 306-309
52. Ferrari C et al. (1995) Cabergoline: a new drug for the treatment of hyperprolactinaemia. Hum Reprod 10: 1647-1652
53. Colao A et al. (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349: 2023-2033
54. Ferrari C et al. (1992) Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 126: 589-594
55. Muratori M et al. (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Endocrinol Invest 20: 537-546
56. Cannavò S et al. (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenomas. J Endocrinol Invest 22: 354-359
57. Biswas M et al. (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol 63: 26-31
58. Robert E et al. (1996) Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 10: 333-337
59. Ricci E et al. (2002) Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 16: 791-793
60. Pinzone JJ et al. (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85: 3053-3057
61. Berezin M et al. (1995) Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J Endocrinol Invest 18: 436-441
62. Walsh JP and Pullan PT (1997) Hyperprolactinaemia in males: a heterogeneous disorder. Austr NZ J Med 27: 385-390
63. Somma M et al. (1981) Prolactinoma in the male. Preoperative evaluation of 40 patients [French]. Neurochirurgie 27: 37-39
64. Eversmann T et al. (1981) Hyperprolactinemia in the male: clinical aspects and therapy [German]. Schweiz Med Wochenschr 111: 1782-1789
65. Spark RF et al. (1982) Hyperprolactinaemia in males with and without pituitary macroadenomas. Lancet 2: 129-132
66. Hulting AL et al. (1985) Prolactinomas in men: clinical characteristics and the effect of bromocriptine treatment. Acta Med Scand 217: 101-109
67. Grisoli F et al. (1980) Prolactin secreting adenoma in 22 men. Surg Neurol 13: 241-247
68. Chattopadhyay A et al. (2005) Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary 8: 147-154
69. Di Somma C et al. (1998) Bone markers and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 83: 807-813
70. Colao A et al. (1996) Chronic treatment with CV 205-52 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol 135: 548-552
71. De Rosa M et al. (1998) Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 138: 286-293
72. Colao A et al. (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89: 1704-1711
73. De Rosa M et al. (2006) The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol 64: 307-313
74. De Rosa M et al. (2004). Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 89: 621-625
75. Calle-Rodrigue RD et al. (1998) Prolactinomas in male and female patients: a comparative clinico-pathology study. Mayo Clin Proc 73: 1046-1052
76. Delgrange E et al. (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82: 2102-2107
77. Parkes D (1980) Side effects of bromocriptine. N Engl J Med 302: 749-750
78. Webster J (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 14: 228-238